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ABSTRACT
THE COMBINED EFFECTS OF GENISTEIN AND DAIDZEIN ON ADIPOCYTE
DIFFERENTIATION
MAY 2014
OUMOU HABYBAT KONE, B.S., UNIVERSITE DE OUAGADOUGOU
M.S., UNIVERSITY OF MASSACHUSETTS, AMHERST
Directed by professor Young-Cheul Kim

Dietary soy isoflavones have been shown to ameliorate insulin resistance and Type 2 diabetes.
However, many in vitro studies used supra-physiological concentrations of individual
isoflavones that make it difficult to interpret the results as potential mechanisms in vivo. Since
the insulin-sensitizing effects of thiazolidinediones, anti-diabetic drugs, have been shown to be
mediated through activation of peroxisome proliferators-activated receptor gamma (PPARγ), the
key transcription factor for adipocyte differentiation, we examined the effects of the two main
soy isoflavones genistein and daidzein either as individual compound or combined on adipocyte
differentiation and PPARγ expression, as well as whether the Wnt/β-catenin signaling pathway is
the underlying molecular mechanism. In 3T3-L1 cells, genistein and daidzein significantly
enhanced adipocyte differentiation. Similarly the expression of PPARγ increased particularly at
20 µmol/L. The stimulatory effect is greater when the two isoflavones are combined, indicating a
synergistic effect. Genistein and daidzein also increased the relative abundance of insulinresponsive glucose transporter 4 (GLUT4) mRNA with a greater effect when combined. Wnt10b
expression was not affected by soy isoflavones treatments, while Wnt5b expression was only
increased by the combination of genistein and daidzein. Our results suggest, that the combination
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of soy isoflavones has a greater effect in increasing the newly formation of adipocytes that are
highly insulin-sensitive via an increase in PPARγ expression as well as increasing the expression
of GLUT4. However, genistein and daidzein actions on Wnt signaling remain unclear. These
data further support the epidemiological findings for the beneficial effect of soy consumption on
insulin sensitivity.
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CHAPTER1
BACKGROUND
1.1 Overview
The World Health Organization estimates that by the year 2025, there will be about 300 million
individuals affected by Type 2 Diabetes Mellitus (T2DM) worldwide [1]. T2DM is a disorder of
glucose and lipid metabolism, contributing to the development of severe health complications
including disorders of microvascular system (retinopathy, neuropathy and nephropathy) and
macrovascular system (coronary heart disease, atherosclerosis and stroke). These complications
lead to a significant reduction in quality of life and account for the excess mortality; more than
75% of people with T2DM die prematurely of cardiovascular disease [2]. Insulin resistance, an
inability of insulin to stimulate glucose utilization in insulin target tissues such as adipose and
muscle is considered to be the primary metabolic defect of T2DM and is highly correlated with
obesity; enlarged adipocytes in obesity are shown to be defective in insulin signaling and thus
insulin resistant, predisposing to T2DM [3]. In addition, the impairment of proliferation and
differentiation of adipocytes has been reported in insulin resistant subjects [4]. Thus, insulin
resistance and T2DM can be triggered by a failure of adipocytes to differentiate into new
adipocytes. Thiazolidinediones (TZD), a class of anti-diabetic drugs improve glycemic control
by activating a nuclear receptor peroxisome proliferator activated receptor-γ (PPARγ), which is
highly expressed in adipose tissues and also a key regulator of adipocyte differentiation. In
insulin resistant fat depots, TZD have been shown to enhance adipocyte differentiation and
opposes the actions of adipokines that mediate insulin resistance [5]. The metabolic effects of
TZD include enhanced insulin signaling, resulting in increased glucose uptake and metabolism
1

coupled with reduced release of free fatty acids into the circulation. One of the mechanisms of
TZD to increase insulin sensitivity is to enhance the differentiation with small and insulinresponsive adipocytes. However, their strong affinity for PPARγ, has been shown to promote
weight gain, an adverse side effect of the drugs [6; 7]. Thus, there have been increasing efforts
to identify natural compounds with fewer side effects [8]. Epidemiological data strongly suggest
that consumption of plant-based foods rich in isoflavones like soybeans provide beneficial
effects for human health [9]. Animal and human studies have been conducted to investigate
anti-diabetic effects of soybeans and their actions [10; 11; 12; 13]. Soya-containing diets were
associated with an improvement in insulin resistance, glycemic control and weight loss [14].
The biological action of isoflavones involves several mechanisms of action and cellular
signaling pathways such as the Wnt/β-catenin signaling pathway that represses adipogenesis
[15]. Although individual effects of isoflavones on adipocyte differentiation have been studied,
most of the studies have considered supra-physiological concentrations; however, it is not clear
whether the combination of the two main soy isoflavones has a synergistic effect on adipocyte
differentiation and insulin sensitivity, and whether the effect is mediated by the Wnt/β-catenin
signaling pathway. Therefore, our focus was to determine in 3T3L-1 mouse pre-adipocytes, (1)
the extent to which the combination of low doses of genistein and daidzein affect adipocyte
differentiation and insulin sensitivity; and (2) the extent to which the Wnt/β-catenin signaling
pathway is the molecular mechanism through which genistein and daidzein treatment promote
adipocyte differentiation and insulin sensitivity.
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1.2 T2DM: causes and risk factors
T2DM is characterized by hyperglycemia and hyperlipidemia [16–18]. It prevalence has reached
epidemic proportions worldwide [19]. In the U.S, the incidence of T2DM has increased by about
33% over the past decade [20, 21]. Obesity and insulin resistance strongly predispose an
individual to T2DM with a progressive increase of fasting glucose levels. According to the
WHO, 44% of the diabetes burden, is attributable to overweight and obesity [22]. Insulin
resistance is a major feature of T2DM and develops in multiple organs, including adipose tissue.
The onset of hyperglycemia and T2DM is often preceded by many years of insulin resistance.
Obesity plays a pivotal role in this phenomenon, providing an important link between fat cell
accumulation and differentiation and T2DM [23]. Newly formed adipocytes are highly insulin
sensitive and less inflammatory, while old adipocytes are associated with an increase in proinflammatory response, which can promote insulin resistance [5]. The inability of adipocyte
differentiation to replace poorly functioning adipocytes has been identified in common metabolic
diseases such as T2DM and obesity. It has been shown that approximately 10% of adipocytes
turn over in human adipose tissue each year, which indicates that ensuring the healthy newly
formed adipocytes could substantially improve metabolic diseases [23].

1.3 Adipocyte differentiation
White adipose tissue is the major energy reserve in higher eukaryotes, and storing triacylglycerol
in periods of energy excess and its mobilization during energy deprivation are its primary
purposes. It is also considered to be secretory organ releasing factors called adipokines that
regulate several physiological processes. For the past twenty years, many in vitro studies have
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been conducted to investigate various molecular aspects of adipocyte differentiation. Various
pre-adipocyte cell lines and primary fat cells cultures have been used. Table 1 summarizes the
characteristics of the most commonly employed pre-adipocyte cell models.

Table 1. In vitro models of adipocyte differentiation (Source: GREGOIRE, SMAS, AND SUL
Volume 78)
Cell Lines

Origin/Stage of Development

CH3 10T/1/2

Mouse embryo†

3T3-L1

Inducing Agents Used for
Differentiation
Demethylating agent 5*azacytidine

Reference
Number
4,5

6

17- to 19-day disaggregated mouse
embryo

10% FBS, Dex and MIX,
insulin (high concentration)
7,8

3T3-F442A
Same as above

10% FBS, insulin

Epididymal fat pads of adult ob/ob
mouse
Sources/Age

8% FBS, insulin, and T3

Ob17

Primary
Cultures
Rat

9
Reference

Subcutaneous, epididymal,
retroperitoneal/newborn
(48 h), 4 wk old, or adult

Inducing Agents used for
Differentiation
Insulin (low concentration in
10% FBS, high concentration in
serum free, accelerated)

Mouse

Subcutaneous/8–12 day old

Serum free; insulin, HDL, Dex

13

Rabbit

Perirenal/4 wk old

Serum free; insulin, Dex

10, 11, 12,

14

Human

Serum free; insulin (high
concentration) and
glucocorticoids

Subcutaneous (abdominal)/ variable age

15,16,10
FBS: fetal bovine serum; MIX, methylisobutylxanthine; Dex: dexamethasone; HDL, high-density lipoprotein; * Totipotent cell
line. † Multipotent.

Owing to their convenience and traceability, pre-adipocyte cell lines like 3T3-L1 have been used
widely to study pre-adipocyte biology. Even though, primary cell lines reflect better the in vivo
context due to their pluripotency stage, they do not undergo continuous passage. Moreover,
proliferation and differentiation of primary pre-adipocytes is influenced by the anatomic site of
the depots and the age of the donor. In particular, aging reduces replicative ability of primary
4

pre-adipocytes in cell culture [Djian et al., 1983]. Importantly, clonal cell lines like 3T3-L1 are
homogenous in terms of cellular population, and their cell types are all at the same differentiation
stage [24]. This allows a homogeneous response to treatments. Besides, these cells can be
passaged indefinitely, which provides a consistent source of pre-adipocytes for study. For all
these reasons, we have chosen 3T3-L1 cells as a cell model for this study.

During the growth phase, cells of pre-adipocyte lines are morphologically similar to fibroblasts.
At confluence, induction of differentiation by appropriate treatment leads to drastic cell shape
changes. The pre-adipocytes are converted to a spherical shape, accumulate lipid droplets, and
progressively acquire the morphological and biochemical characteristics of the mature white
adipocyte (Figure 1, [25]). The nature of the induction is dependent on the specific cell culture
model system employed (confer Table 1).

Multipotent
o Chrondoblast
o Osteoblast
o Myoblast

Determined
o Growth arrest
o Post-confluent mitoses
o Myoblast
Commited

Terminal differentiation

Figure 1. Stages in adipocyte differentiation
5

During adipocyte differentiation, acquisition of the adipocyte phenotype is characterized by
chronological changes in the expression of numerous genes (Figure 2). This is reflected by the
appearance of early, intermediate, and late markers and triglyceride accumulation. These changes
take place primarily at the transcriptional level, although post-transcriptional regulation occurs
for some adipocyte genes [26].

Two transcription factors, CCAAT/enhancer binding protein alpha (C/EBPα) and PPARγ, have
been shown to transactivate adipocyte specific genes. During the terminal phase of
differentiation, adipocytes in culture markedly increase de novo lipogenesis and acquire
sensitivity to insulin. The activity, protein, and mRNA levels for enzymes involved in
triacylglycerol metabolism include: ATP citrate lyase, malic enzyme, acetyl-CoA carboxylase,
stearoyl-CoA desaturase (SCD1), glycerol-3- phosphate acyltransferase, glycerol-3-phosphate
dehydrogenase, fatty acid synthase, and glyceraldehyde-3-phosphate-dehydrogenase increase 10to 100-fold [ 27, 28]. Glucose transporters [29], insulin receptor number, and insulin sensitivity
increase with the degree of differentiation. In addition to increases in gene expression directly
related to lipid metabolism, adipocytes also synthesize other adipose tissue-specific products
involved in fatty acid transport. These include the following: aP2, an adipocyte specific fatty acid
binding protein; FAT/CD36, a putative fatty acid transporter [30,31].

6

Figure 2. Molecular events during adipocyte differentiation,

1.4 Failure of adipocytes to differentiate in T2DM
A major function of the adipose organ is to store excess energy as triglycerides under conditions
of nutrient excess [32]. However, in response to prolonged periods of calorie excess, the adipose
organ may become overloaded and unable to recruit new fat cells, resulting in adipose tissue
hypertrophy of existing fat cells and increased ectopic fat deposition in tissues such as skeletal
muscle, liver, myocardium, and pancreas. Fat depots consist of multiple cell types. In addition to
fully differentiated mature adipocytes that are able to synthesize fatty acids, metabolize glucose,
and take up and store triglyceride from the blood, adipose tissues contain multipotent precursor
7

cells that can be induced to differentiate into mature adipocytes. The adipocyte population within
a fat depot ranges from small, newly differentiated, highly insulin responsive adipocytes to large,
lipid-filled, relatively insulin resistant adipocytes. In insulin resistant states, such as obesity and
T2DM, fat depots contain a high proportion of large-lipid filled adipocytes. For example,
independent of total body fat, Pima Indians with larger abdominal fat cells are more insulin
resistant and more likely to develop diabetes than those with smaller fat cells [33; 34]. People
with enlarged subcutaneous adipocytes are more hyperinsulinemic and glucose intolerant and are
at increased risk for the development of T2DM, relative to those with similar degrees of
adiposity but smaller adipocytes. It has been hypothesized that insulin resistance develops
because of alterations in the partitioning of fat between adipose tissue and muscle or liver [35]. It
is also known that a lack of adipose tissue is similarly associated with insulin resistance and
increased risk for development of T2DM [36; 37]. Similarly, in humans, lipodystrophy is
associated with insulin resistance and often T2DM [38].

The anti-diabetic drug TZD constitutes a good example of how adipocyte differentiation can
reverse insulin resistance. These drugs act by activating PPARγ in fat depots, which potentiates
the insulin-mediated differentiation program, resulting in increased number of small insulinsensitive fat cells. In large, insulin resistant adipocytes, TZD opposes pro-inflammatory cytokine
production and promotes apoptosis (Figure 3), [5].
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Pre-adipocytes

Potentiates insulin
stimulated differentiation

Insulin-responsive small
adipocytes

PPARγ

Insulin-resistant
large adipocytes

Blocks lipolysis and
inflammatory cytokines
release. Pro-apoptotic

TZD

Figure 3. Regulation of adipose depot cell phenotype by thiazolidinedione activation
of PPARγ

Although TZD is effective in reducing insulin resistance and thus treating T2DM, an important
drawback is that they increase weight gain because of excessive adipocyte differentiation
(insulin-sensitive small adipocytes). It is important, therefore, to continue to research safer
alternatives to TDZ. For example, it is known that soy-rich diets decrease weight gain and
insulin resistance; therefore, they might constitute a safer alternative to treat insulin resistance
and T2DM. Discovery of the molecular mechanism through which increased soy consumption
bring about these favorable effects is not completely understood. In particular, the importance of
bioactive compounds found in soy, such as genistein and daidzein, on adipocyte differentiation
require additional investigation.
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1.5 The dietary soy isoflavones genistein and daidzein

1.5.1 Sources, structure and metabolism
Isoflavones are a class of polyphenols that are biologically active plant-derived compounds.
Many of them structurally and functionally mimic estrogens [39] and, therefore, are called
phytoestrogens. Isoflavones are mainly found in the soybean—the most important dietary source
of phytoestrogens for humans, cattle and rodents. They have a non-steroidal structure, but
possess a phenolic ring that enables them to bind to the estrogen receptor (ER) and act either as
estrogen agonists or antagonists [40; 41]. The three principal isoflavones found in soy are
genistein, daidzein and glycetein, generally in a concentration ratio of 1:1:0.2 [42]. Genistein
(4,5,7-trihydroxyisoflavone) and daidzein (4',7-Dihydroxyisoflavone), the most abundant
isoflavones in soybean, are also present in several other plants which represent excellent sources
of phytoestrogens such as lupine (Lupinus spp.), favabean, (Viciafaba) and kudzu (Pueraria
lobata) [43]. After ingestion, genistein and daidzein are respectively released from the glucoside
genistin and daidzin by acid hydrolysis in the stomach or by microflora hydrolysis in the
intestine. The resulting aglycone from genistein can either be absorbed or further metabolized to
specific metabolites (Dihydrogenistein, 5-hydroxy-equol) [44]. Daidzein can be converted to its
end metabolite S-equol [7-hydroxy-3-(49-hydroxyphenyl)-chroman] in some humans based on
the presence of certain intestinal bacteria.
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Figure 4. Structure of soy isoflavones and their metabolites
(source: http://www.isoflavones.info/isoflavones-metabolism.php)

1.5.2 Bioavailability of isoflavonoids
Isoflavones are absorbed only as aglycones in the intestine and the glycosylated isoflavones can
be hydrolyzed to the aglycone forms by β-glucosidases associated with gut bacteria and by
lactase enzyme in the small intestine [45]. Studies on metabolism and bioavailability of
isoflavonoids have been contradictory regarding the absorption of aglycones versus glycosides. It
was reported that soy isoflavone aglycones are better absorbed than their corresponding
glucosides in Japanese men and women [46]. Peak plasma concentrations were 4 times higher
and occurred 2h earlier for both genistein and daidzein than for their glucoside counterparts.
However, another study has shown that the apparent bioavailability of genistein and daidzein
was not different when consumed as either raglycone or glucoside by American women [47].
Moreover, a better absorption of daidzein when consumed as a glucoside, where the fractional
absorption of the daidzein aglycone was 11.6 versus 38.9 for the glucoside has been suggested
[48]. A plausible explanation for this controversy is that isoflavone metabolism is more complex
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than it appears since it depends on many other factors related mainly to individuals and their
diets. Food matrix/diet, dose, frequency of ingestion, age, gender, microfloral subgrouping and
gut transit time are factors influencing metabolism and bioavailability of isoflavones and
therefore should be taken into account when performing clinical trials with isoflavones [49].

1.5.3 Soy bioactives and health benefits
Epidemiological data strongly suggest that consumption of plant-based foods rich in isoflavones
provides beneficial effects for human health [44]. Thus, much attention has been given to
investigating the effects of these compounds in human physiological and pathological states.
Soybean contains between 0.6 and 3.8g isoflavones/kg fresh weight [50]. In populations having a
high soy diet like the Japanese population, the plasma concentration of soy isoflavones can reach
2.4 µmol/L [51]. In humans, plasma or serum levels of genistein from soyfood ingestion range
from less than 1 µmol/L to about 5 µmol/L (Wiseman et al., 2004). Phytoestrogen intake varies
from 20–50 mg/day in East and Southeast Asia to 0.15–3mg/day in the US and 0.49–1mg/day in
some European countries (Klein and King, 2007), thus the safety dose was retained as 50
mg/day. Daidzein and genistein exert various actions in the organism, mainly related to
ameliorating some post-menopausal problems, such as hot flushes and bone loss, preventing
breast cancer, reducing risk of cardiovascular diseases and affecting insulin secretion and action
[52; 53; 54]. The complexity of their biological action suggests the involvement of several
mechanisms of action and cellular signaling pathways such as estrogen-like activity, tyrosine
kinase inhibitory effect, 5'AMP-activated protein kinase (AMPK) pathway and Wnt signaling
pathway.
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In a short (8 weeks) randomized crossover clinical trial including 42 post-menopausal women
with the metabolic syndrome[10], soy nut consumption (soy nut-DASH diet) significantly
decreased the homeostasis model of assessment-insulin resistance score compared with the
control group on a red meat-DASH diet (-12.9±0.9; P< 0.01). Consumption of soy-nut also
reduced fasting plasma glucose more significantly than did the control diet (-5.1±0.6%; P<0.01).
The soy-nut regimen decreased LDL cholesterol more than did the control diet (-9.5±0.6%;
P<0.01), and significantly reduced serum C-peptide concentrations compared with control diet (8.0±2.1; P<0.01). In a double-blind controlled trial [10], 39 postmenopausal women were
randomized to soy supplementation (20g soy protein plus 160mg isoflavones with 96mg
available as aglycones) or to a casein placebo without isoflavones for 3 months. Soy
supplementation reduced total and subcutaneous abdominal fat, and IL-6. No difference between
groups

was

noted

for glucose metabolism,

CRP,

TNF-α,

leptin,

or adiponectin.

The effects of soy isoflavone on insulin sensitivity and adipocytokines in high-fat-diet-induced
insulin resistant (IR) rats were studied by using 80 male Sprague Dawley rats [11]. The rats were
randomly assigned into a basal diet fed group and high-fat diet fed group. The high-fat-dietinduced insulin resistant rats were assigned into IR model control group and three soy
isoflavones-treated groups with different dosages. 30 days later, the fasting blood glucose,
insulin and adipocytokines in serum and mRNA expressions of adipocytokines in perirenal white
adipose tissue were measured. The Homeostasis Model Assessment of IR was calculated. The
administration of 450 mg kg (-1) d (-1) soy isoflavones decreased the body weights and
depositions of visceral adipose tissue as well as improved insulin resistance in high-fat-dietinduced IR rats. The mechanisms were associated with soy isoflavones-regulating the expression
of adipocytokines, including adiponectin, leptin, resistin and TNF-α.
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In a randomized trial including 77 subjects for 12 months [12], a soy-based meal replacement
(MR) plan showed a significant decrease in percentage weight loss (4.577 ±0.81%) compared
with an individualized diet plan (IDP; as recommended by the American Diabetes Association)
(2.257±0.72%). Controlling for baseline levels, hemoglobin A1C level improved by
0.497±0.22% for those receiving MR when compared to IDP group (P<0.05). A greater number
of subjects in MR group reduced their use of sulfonylureas (P<0.0001) and metformin (P<0.05)
as compared to IDP group. High-sensitivity C-reactive protein (hs-CRP) decreased by 25.0%
(P¼0.019) in MR group compared to 18.7% (P¼0.179) in IDP group at 12 months.
Genistein (0.02%, w/w) and daidzein (0.02%, w/w) supplements increased insulin/glucagon ratio
and C-peptide level with preservation of insulin staining β-cell of pancreas in the NOD mice
[55]. In the liver, genistein and daidzein supplements resulted in lowering glucose-6-phosphatase
and phosphoenolpyruvate carboxykinase activities, while increasing two lipogenic enzymes
activities, malic enzyme and glucose-6-phosphate dehydrogenase, compared to the control
group. Significantly, genistein and daidzein supplementation lowered the activities of fatty acid
β-oxidation and carnitine palmitoyltransferase in these mice. Genistein and daidzein also
improved plasma triglyceride and free fatty acid concentrations compared to the control group.
Table 2 summarizes the state of art in soy isoflavones effects on adipogenesis.
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Table 2. Literature review
Human/Animal/Cell
Lines

Compounds/
Concentrations
Daidzein/50mg/kg BW

Author/Year

Effects

Cao YC et al. /2013

Ovariectomized rats

Genistein/ 0.1%

Joo Sun Choi et al.
/2012

Freshly isolated
Rat adipocytes

Genistein/ 50 µMol

Szkudelska et
al./2011

C57BL/6J mice

Daidzein/ 0.1; 0.5; 1 and
2 g per kg diet

Kim, MH /2011

Obese postmenopausal women
Human adipose
tissue-derived
mesenchymal stem
cell
Murine adipocytes

Genistein/ 60.8mg/day

Llaneza et al. /2011

Genistein/ 100 µMol

Kim et al. /2010

Decrease weight gain,
visceral fat and IL-6
levels induced by
ovariectomy. Lower
levels of TNF-alpha,
leptin and blood lipids
compare to the control
group
Smaller adipocytes size,
decrease insulin resistance
index, increase hepatic
fatty acid synthetase
activity, increase
succinate dehydrogenase
activity and rate of β
oxidation in fat tissues
Inhibition of insulinstimulated glucose uptake
and reduction of ATP
levels
Lower insulin and blood
glucose levels. Inhibit
adiposity, augment
antisteatohepatitic leptin
and adiponectin mRNA
levels, reduce the mRNA
or concentration of
steatotic tumor necrosis
factor a and ghrelin
Reduction of serum leptin
levels
Inhibition of adipogenic
Differentiation

genistein40 µMol

Niwa et al./2010

Primary human
preadipocytes

Genistein 50 µMol

Park et al./2009

3T3-L1 adipocytes

Genistein with vitamin D

Rayalam et al./ 2008

Human cells
3T3L1 cells

Genistein/6.25 µMol
+Quercetin/12.5 µMol
+Resveratrol/12.5 µMol

Rat adipocytes

Genistein/ 100 µMol

Szkudelska et
al./2008

3T3-L1 adipocytes

Genistein 10 µMol

Nomura et al. /2008

Ovariectomized rats
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Inhibition of leptin
secretion
Inhibition of lipid
accumulation

Inhibition of lipid
accumulation and
induction of apoptosis

Enhance Inhibition of
lipid accumulation and
decrease glycerol-3phosphate activity
compare to individual
Inhibition of the
antilipolytic
action of insulin
Abrogation of GLUT4
mediated
glucose uptake

Mechanisms
described

Down regulation of
carbohydrate
responsive element
binding protein, its
upstream gene liver
X receptor beta and
its target genes
encoding for
lipogenic enzymes
Mitochondrial
dysfunction
Wnt/β–catenin
signalingpathway

Down-regulation of
PPARγ, C/EBPα and
glycerol-3-phosphate
dehydrogenase
Suppression of
PPARα, C/EBPα, and
enhancing
vitamin D receptor
expression

Activation of protein
kinase A and
elevation of cAMP
levels
Tyrosine kinase
inhibition activity

3T3-L1 adipocytes

Genistein with resveratrol

Rayalam et al. /2007

Non-obese diabetic
mice

genistein (0.02%,w/w)

Choi et al. / 2007

daidzein (0.02%, w/w)

3T3-L1 adipocytes

Genistein with
Guggulsterone

Yang et al./ 2007

Ovariectomized
C57/BL6
female mice

Genistein 1,500 mg/kg

Kim et al./2006

3T3-L1 mouse
embryo fibroblasts
MC3T3G2/PA6adipocytes
3T3-L1 adipocytes

Genistein 400 µMol

Kim et al./2006

Genistein 50 µMol

Bazuine et al./2005

Genistein 100 µMol

Harmon and
Harp/2001

3T3-L1 adipocytes

Genistein 200 µMol

3T3-L1
adipocytes

Genistein with green tea
catechin andcapsaicin

Inhibition of
adipogenesis; induction
of apoptosis; and
stimulation of lipolysis
Lower Blood glucose
levels by about 40%,
increase insulin/glucagon
ratio and C-peptide level
with preservation of
insulin staining β-cell of
pancreas, o improved
plasma triglyceride and
free fatty acid (FFA)
concentrations
Apoptosis and
suppression of
differentiation and
adipogenesis

Down-regulation of
PPARγ and C/EBPα

Production of active
caspase3. Expression
of pro-apoptotic Bax.
Release of
cytochrome c

Reduction of food
intake,body
Weight and fat pad
weight.
Adipose tissue apoptosis
Inhibition of glucose
uptake
Increased lipolysis

Tyrosine kinase
inhibition activity

Hwang et al./2005

Inhibition of adipocyte
differentiation

Hwang et al. /2005

Suppression of
differentiation,
adipogenesis and lipid
accumulation, and
induction of apoptosis

Activation of AMPactivated
protein kinase
Release of
intracellular reactive
oxygen species and
activation of AMPK
pathway

Physical activity, diet and daily oral intake of a soy isoflavones extract, that contains 60.8mg of
genistein, have shown beneficial effect on serum leptin, adiponectin and TNFα in healthy obese
post-menopausal women after 6 months of treatment compared with a control group [56].
Twelve weeks of daidzein therapy (50mg/kg/day) decreased weight gain, visceral fat, the
HOMA-IR index and IL-6 levels in ovarectomized rats compare with the control group. Rats
which had received daidzein therapy had lower levels of TNF-α, leptin and blood lipids. IL-6
levels positively correlated with the HOMA-IR index in all of the rats after adjustment for body
weight (r =0.495; p =0.016) [57].

.
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In 3T3-L1 cells, daidzein enhanced adipocyte differentiation and PPARγ expression in a dosedependent manner. It also dose-dependently increased insulin-stimulated glucose uptake and the
relative abundance of insulin-responsive glucose transporter 4 (GLUT4) and insulin receptor
substrate 1 (IRS-1) mRNA. In C3H10T1/2 mouse cells, daidzein at 1 µmol/L and higher
significantly increased adipocyte differentiation and insulin-stimulated glucose uptake [58].
Furthermore, daidzein also up-regulated PPARγ-mediated transcriptional activity, and restored
the PPARγ antagonist-induced inhibition of aP2 and GLUT4 mRNA levels.
In mice, genistein supplementation improved hepatic steatosis and gene expression involved in
the fatty acid catabolism (59, 60).
Most of the in vitro studies about genistein effects on adipogenesis have considered high
concentrations that inhibit adipocyte differentiation and increase lipolysis. Yang et al., 2007,
showed that genistein alone (50µmol/L and 100µmol/L) or in combination with guggulsterone
(25µmol/L and 50µmol/L) suppressed differentiation, adipogenesis and lipid accumulation in
3T3-L1 adipocytes. The same observation was found with genistein at 50, 100 and 200µmol/L in
3T3L-1 adipocytes (Hwang et al., 2005). Concerning the mechanisms involved, Kim et al., 2010,
reported that genistein inhibited adipogenic differentiation of human adipose tissue-derived
mesenchymal stem cell via Wnt/β-catenin signaling pathway, in an estrogen receptor-dependent
manner. Lipid accumulation was also inhibited by genistein in a dose dependent manner, through
down-regulation of adipocyte specific transcription factors such as PPARγ, C/EBPα and
glycerol-3-phosphate dehydrogenase (Park et al., 2009).
The supra-physiological concentrations of genistein used in these studies above, result in
decreased adipogenesis and increased lipolysis. However, increasing lipolysis lead to an increase
release of free fatty acid which triggers insulin resistance and inflammation. Therefore, finding a
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safer way to prevent obesity and the metabolic syndrome is needed. While clinical studies have
shown beneficial effects of soy isoflavones supplementation in both weight loss and insulin
sensitivity, none of the studies have considered looking at a potential synergism of action
between the main soy isoflavones genistein and daidzein. Xin Dong et al., 2013 showed that
daidzein and genistein have a synergistic effect on inhibiting cell proliferation and inducing
apoptosis of prostate cancer cells. 25 µmol/L daidzein/ 50 µmol/L genistein significantly
increased the apoptotic effects on C4-2B cells although they did not show any effect when used
individually. We hypothesized that genistein and daidzein will have synergistic action in
promoting insulin sensitivity via an increase in the master regulator of adipocyte differentiation,
PPARγ and a down regulation of specific Wnt proteins. The expression of PPARγ has been
shown to be influenced by the Wnt/β-catenin signaling pathway [61].

1.6. The Wnt/β-catenin signaling pathway and adipocyte differentiation
The field of adipogenesis has seen an increase in the number of reports involving locally secreted
or circulating extracellular factors as regulators of pre-adipocyte differentiation [62]. One of the
extracellular signaling pathways now known to affect adipogenesis is the Wnt pathway.
Wnt are an evolutionarily conserved family of secreted lipidated glycoproteins with wellestablished roles in cellular proliferation, differentiation, and polarity during embryogenesis [63,
64]. More recently, Wnt signaling has been shown to modulate additional developmental and
physiological processes, including aspects of adipocyte biology [65; 66]. Although Wnt can
inhibit pre-adipocyte differentiation through both β-catenin-dependent and independent
mechanisms [15], current genetic evidence supports β-catenin as a particularly crucial regulator
of adipogenesis [67]. In Wnt/β-signaling pathway, β-catenin plays a central role as a

18

transcriptional co-activator. Upon binding of Wnt ligands to frizzled receptors and low density
lipoprotein

receptor-related

protein

(LRP)

co-receptors,

cytoplasmic

β-catenin

is

hypophosphorylated, stabilized, and translocated into the nucleus where it binds to and coactivates members of the T-cell factor/lymphoid-enhancing factor (TCF/LEF) family of
transcription factors to direct target gene expression (Figure 5, [68]).

Figure 5. Schematic description of canonical Wnt signaling

In vitro and in vivo data characterized the role of Wnt-signaling molecules in the regulation of
adipocyte differentiation. In human and murine pre-adipocytes, a down-regulation of Wnt/βsignaling is a prerequisite in order to initiate adipogenesis. Over-expression of Wnt10b in mouse
pre-adipocytes inhibited the expression of C/EBPα and PPARγ and kept pre-adipocytes in an un-
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differentiated state in vitro and in vivo [69]. Conversely, inhibition of Wnt-signaling was
sufficient to facilitate spontaneous differentiation of adipocytes and trans-differentiation of
myoblasts into adipocytes. Cawthorn et al. demonstrated that suppression of C/EBPα and PPARγ
by TNFα coincides with enhanced expression of several downstream targets of Wnt/β-catenin
signaling [61]. Transgenic over-expression of Wnt10b in mice, under the control of the FABP4
promoter led to a tissue specific expression of Wnt10b in white adipose tissue. These mice were
found to have less adipose tissue on normal carbohydrate diet. Human genetic studies have
revealed an association of a heterozygous loss of function mutation (C256Y) in the Wnt10b gene
with obesity. Mature human primary adipocytes were found to secrete Wnt10b and Wnt3a and to
inducel Wnt/β-signaling in target cells [70]. Isoflavones at supra-physiological concentrations
can exert their anti-adipogenic effect through Wnt-signaling pathway.
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CHAPTER 2
EFFECT OF COMBINED GENISTEIN AND DAIDZEIN ON ADIPOCYTE
DIFFERENTIATION

2.1 Literature Review
Diabetes mellitus is the most prevalent metabolic syndrome world-wide with an incidence
varying between 1 to 8% [73, 74]. In the US, the incidence of T2DM has increased by about
33% over the past decade and is expected to increase further [75, 76]. The disease arises when
insufficient insulin is produced, or when the available insulin does not function properly. Thus
diabetes is characterized by hyperglycemia resulting in various short-term metabolic changes in
lipid and protein metabolism and long-term irreversible vascular changes. Currently available
therapies for diabetes include insulin and various oral anti-diabetic agents such as sulfonylureas,
biguanides, α-glucosidase inhibitors, thiazolidinedione and glinides, which are used as
monotherapy or in combination to achieve better glycemic regulation. Many of these oral antidiabetic agents suffer from various adverse effects, thus, managing diabetes without any side
effects is still a challenge, and the search for more effective and safer therapeutic agents in
eradiating diabetic syndromes is much needed. Dietary factors that enhance insulin sensitivity
are a novel approach to treat the onset of metabolic disorders such as diabetes and obesity.
Therefore, the identification and characterization of natural compounds which could improve
insulin sensitivity is important for the treatment and prevention of T2DM. Soy is an important
agricultural crop in the U.S that could have important health benefits. Clinical and
epidemiological studies have shown that soy intake is associated with reduced incidence of
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diabetes and T2DM-related symptoms [77, 78]. Dietary supplementation with isoflavones
reduced insulin resistance and improved glycemic control in T2DM patients and also lowered
low density lipoprotein cholesterol [79]. Soy isoflavones have been also shown to improve
glucose tolerance and decrease blood glucose levels in diabetic animal models [80]. These
studies indicate that soy isoflavones may enhance insulin sensitivity. However, the molecular
mechanisms by which isoflavones sensitize the insulin-responsive tissues remain unclear.
Adipose tissue is an important site of both glucose and lipid metabolism. Insulin resistance is
associated with obesity. Systemic insulin resistance is observed in mice lacking insulin-sensitive
glucose transporter 4 (GLUT4) in adipose tissue, suggesting that glucose metabolism in
adipocytes is critical to whole-body glucose homeostasis [81]. Insulin responsiveness is acquired
during the maturation phase of adipogenesis and involves the expression of proteins responsible
for the phenotypic functions of adipocytes, such as GLUT4 [81]. Several genes related to
adipocyte differentiation are decreased in Type 2 diabetic humans [82], suggesting that altered or
impaired adipocyte differentiation may promote the onset of insulin resistance. PPARγ is a key
regulator of adipocyte differentiation [25]. In addition to its regulatory role in adipogenesis,
PPARγ activation modulates the expression of several key molecules involved in insulin
signaling, lipid metabolism and endocrine function in adipocytes. It has been shown that PPARγ
activation mediates the anti-diabetic activities of thiazolidinediones (TZDs) [5]. Dietary
isoflavones has been found to increase PPARγ and GLUT4 protein in adipose tissue and reduced
the severity of diabetes in Zucker diabetic fatty rats [80]. Although individual effects of
isoflavones on adipogenesis have been studied, most of the studies have considered supraphysiological concentrations and none of them has considered the effect of the combination of
the two main soy isoflavones on adipocyte differentiation and insulin sensitivity.
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2.2 Purpose of study
The effect of low doses of the two main soy isoflavones genistein and daidzein on adipogenesis
and GLUT4 expression has not been established. Most of the studies conducted on the effect of
genistein and daidzein on fat cells have considered relatively high concentrations of individual
soy bioactive compounds (50 µmol/L and higher). These supra-physiological concentrations
increase lipolysis, which could be a potential problem in organs like the liver because an increase
lipolysis would increase the amount of FFA taken up by the liver, which could contribute to the
production of reactive oxygen species (ROS). Also, adipocytes secrete adipokines that have
important cellular actions; apoptosis of adipocytes might affect adipokine functions [5].
However, clinical studies have shown the beneficial effect of soy isoflavones consumption on
obesity and diabetes. Animal and human studies have been conducted to investigate anti-diabetic
effects of soybeans and their actions [10; 11; 12; 13]. Soya-containing diets were associated with
an improvement in insulin resistance and glycemic control [14]. Since these two are the main soy
isoflavones and soy isoflavones have been shown to decrease obesity and diabetes in
epidemiological studies, we hypothesize that this beneficial effect may be due to the combined
effect of those two compounds. Our objective here is to determine the extent to which the
combination of low doses of genistein and daidzein exerts an effect on adipocyte differentiation
and gene expression. Our central hypothesis is that genistein and daidzein combined at low
doses will promote preadipocytes differentiation into adipocytes, as demonstrated by an increase
in lipid content, adipocyte specific gene expression and GLUT4 expression, which is mediated by
altering specific Wnt expression.
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2.3 Materials and Methods
2.3.1 Cell Culture Model and Treatments
For the differentiation of 3T3-L1 preadipocytes, cells were grown to 100% confluence in Growth
Media [DMEM (high glucose), 10% Calf Serum, 1% Penicilin/ Streptamycin] replaced every
two days. At two days post-confluence, growth media was changed to Differentiation Media
[DMEM (high glucose), 10% Fetal Bovine Serum, 1% P/S, 1% Insulin, 1% 3-Isobutyl-1methylxanthine 11.5mg/ml, 0.01% Dexamethasone 3.9mg/ml] in the presence or absence of
genistein and daidzein. The combination of 3-Isobutyl-1-methylxanthine (MIX), dexamethasone,
and insulin is known as the standard MDI adipogenic cocktail. At two days post-MDI induction,
media was replaced every two days with post-differentiation media [DMEM (high glucose), 10%
Fetal Bovine Serum, 1% P/S, 1% Insulin, +/-genistein + daidzein]. 3T3-L1 preadipocytes
generally reach 80% differentiation 4 to 6 days post-differentiation.

2.3.2 Oil Red O Staining of Lipids
Cells were harvested on desired days and underwent Oil Red O Staining to quantify lipid
accumulation, as it is an indirect determiner of cell differentiation. Cells, grown on 6-well plates,
were treated with 10% formaldehyde in phosphate buffer solution (PBS) for 1 hour, washed with
60% isopropanol, and completely dried. Then, cells were stained with 0.5% Oil Red O solution
in 60:40 (v/v) isopropanol: H2O, for 30 minutes at room temperature. Finally, wells were rinsed
with distilled water and dried. Optical density was then measured at 490nm, after eluting with
isopropanol, to quantify lipid accumulation.
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2.3.3 RNA Isolation and Analysis
Cells washed with phosphate buffer solution (PBS), were harvested with Trizol Reagent and
stored at -80° C until mRNA isolation. For isolation, samples were thawed and centrifuged with
200µL chloroform. Supernatant was transferred to a fresh tube and centrifuged with isopropanol
(1:1) to precipitate RNA. Isopropanol was removed and the pellet was washed three times with
ethanol by centrifugation. The pellet was then re-suspended in DEPC water and quantified using
a spectrophotometer at 260 nm. 8µg of RNA was used along with SuperScript III reagents to
make cDNA which was stored at -4°C. Polymerase Chain Reaction was performed with primers
for PPARγ, C/EBPα, GLUT4, Wnt5b and Wnt10b (see Table 2). Samples were run on an
agarose gel, and detected using Ultra Violet light. Band intensity was determined using Image J
analysis and adjusted to β-actin.

Table 3. Primer Information
genes
β-actin
GLUT4
PPARγ
Wnt5b
Wnt10b
C/EBPα

sense 5'-3'
AGGCTGTGCTGTCCCTGTATGC

primers
antisense 5'-3'

GATTCTGCTGCCCTTCTGTC
CCAGAGTCTGCTGATCTGCG
GTGCCAACACCAGTTTCGAC
CTGACTTCTGCGAGCGAGAC
GGTGCGCAAGAGCCGAGATAAAG

Temperature/Cycle

ACCCAAGAAGGAAGGCTGGAAA

60/40

ATTGGACGCTCTCTCTCCAA

51/40

GCCACCTCTTTGCTCTGATC

57/40

CTCTCGGGCATCCACAAACT

57/40

CAGCACCAGTGGAAACGACAG

58/40

AGTTCACGGCTCAGCTGTTCCAC

61/40

2.3.4 Statistical Analysis
Samples were collected in duplicate, and differences between the means were determined by
student’s T-test. P-values were considered significant at <0.05.
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2.4 Results
2.4.1 Effect of genistein, daidzein and their combination on adipocyte differentiation
In order to determine the dose-dependent effect of soy isoflavones, post-confluent 3T3-L1 cells
were grown and differentiated in the presence or absence of either genistein, daidzein or
combined genistein and daidzein for 8 days, upon which they were harvested for Oil Red O
staining to measure lipid accumulation. Rosiglitazone, a TZD molecule, was used as a positive
adipocyte differentiation control. Cells not treated with differentiation cocktail served as negative
controls. As shown in Fig. 6, genistein increased adipoyte differentiation at concentrations
between 1 and 20 µmol/L. However the increase is not statistically significant. Daidzein
treatments at all concentrations increased adipocyte differentiation with a significant increase at
20 µmol/L (1.8 fold) as shown in Fig.6. When combined, genistein and daidzein treatments
significantly increased adipocyte differentiation compared to the negative control with a greater
increase obtained with 20 µmol/L treatment (2.4 fold). The combination seems to increase more
adipocyte differentiation compared to the individual compound but the increase is less than that
of rosiglitazione, the antidiabetic drug.
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Figure 6. Genistein,, daidzein and their combinations dose-dependently increased lipid
accumulation in 3T3-L1
L1 preadipocytes
preadipocytes, as measured by Oil Red O staining.
staining
Absorbance of red fat-soluble
soluble stain eluted with 100% is
isopropanol and measured at 490. The values are expressed as
fold changes, compared with control (vehicle), which was arbitrarily set to 1. Each value is the Mean±S.E.M. of the
results from two different plates and is representative of results from at least two different experiments. Means
without a common letters are significantly differ
different (P<0.05)

2. 4.2 Correlation of adipocyte
ipocyte differentiation and adipogenic genes mRNA expression
Since PPARγ and C/EBPα play a key role in adipocyte differentiation, we determined whether
the changes in response to genistein, daidzein and their combination (Fig. 6)
6 correlate with
changes in the expression of PPAR
PPARγ and C/EBPα expressions during the differentiation of 3T33T3
L1 cells. The increase in PPARγγ mRNA expression in 3T3
3T3-L1 cells differentiated with
w MDI plus
genistein is observed at 20 µmol/L
mol/L (Fig. 7A). Daidzein up-regulated PPARγ mRNA expression
at both 20 µmol/L and 50 µmol/L
mol/L (Fig. 7B). Similarly, when treated with genistein and daidzein
combined, PPARγ mRNA expression was enhanced in 3T3
3T3-L1 cells differentiated at a
concentration of 20 µmol/L
mol/L (Fig. 77C). The increase with the combination is greater than that of
individual isoflavone.
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Figure 7. PPARγ mRNA expression in 3T3-L1 cells treated with genistein (A), daidzein (B)
or their combinations (C).
3T-L1 cells were grown and differentiated with the differentiation cocktail in the absence and presence of varying
concentrations of genistein, daidzein and their combination throughout differentiation (0, 1, 5, 10, 20, 50 µmol/L)
for 8 days. Total RNA was extracted at day 8 and subjected to RT-PCR. PPARγ mRNA levels were quantified and
normalized with β-actin mRNA. The values are expressed as fold changes, compared with control (vehicle), which
was arbitrarily set to 1; one independent experiment.

C/EBPα mRNA expression was not enhanced in 3T3-L1 cells differentiated with MDI plus
either genistein or daidzein alone (Fig.8A & B). However, an increase in C/EBPα mRNA
expression was observed when 3T3-L1 cells were treated with genistein and daidzein combined
at a concentration of 20 and 50 µmol/L (Fig. 8C).
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Figure 8. C/EBPα mRNA expression in 3T3-L1 cells treated with genistein (A), daidzein (B)
or their combinations (C).
3T-L1 cells were grown and differentiated with the differentiation cocktail in the absence and presence of varying
concentrations of genistein, daidzein and their combination throughout differentiation (0, 1, 5, 10, 20, 50 µmol/L)
for 8 days. Total RNA was extracted at day 8 and subjected to RT-PCR. PPARγ mRNA levels were quantified and
normalized with β-actin mRNA. The values are expressed as fold changes, compared with control (vehicle), which
was arbitrarily set to 1; one independent experiment.
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2.4.3 Effects of Genistein, daidzein and their combination on GLUT4 mRNA expression
Because PPARγ is the molecular target for TZD antidiabetic drugs that improve insulin
sensitivity and glucose tolerance, we examined whether the increased adipocyte differentiation
by soy isoflavones results in enhanced expression of the gene encoding GLUT4, which is the key
downstream signaling molecule involved in insulin
insulin-stimulated
stimulated glucose uptake in adipocytes. The
expression of GLUT4 mRNA was up-regulated in cells exposed to 20 µmol/L genistein, daidzein
and their combination compared to control cells (Fig. 9). Again the stimulatory effect is greater
for the combination.
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Figure 9. GLUT4 mRNA expression in 3T3-L1 cells treated with genistein (A), daidzein (B)
or their combinations (C).
3T-L1 cells were grown and differentiated with the differentiation cocktail in the absence and presence of varying
concentrations of genistein, daidzein and their combination throughout differentiation (0, 1, 5, 10, 20, 50 µmol/L)
for 8 days. Total RNA was extracted at day 8 and subjected to RT-PCR. PPARγ mRNA levels were quantified and
normalized with β-actin mRNA. The values are expressed as fold changes, compared with control (vehicle), which
was arbitrarily set to 1; one independent experiment.
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2.4.4 Effects of Genistein, daidzein and their combination on the Wnt signaling pathway
In Order to determine whether soy isoflavones effects on adipocyte differentiation is mediated
through the Wnt-β signaling pathway, we determined the mRNA expression of Wnt-5b which is
adipogenic and Wnt 10 b which represses adipocyte differentiation. Soy isoflavones slightly
increase the expression of Wnt-5b compared to control cells at 20 µmol/L (Fig.10)
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Figure 10. Wnt5b mRNA expression in 3T3-L1 cells treated with genistein (A), daidzein (B)
or their combinations (C).
3T-L1 cells were grown and differentiated with the differentiation cocktail in the absence and presence of varying
concentrations of genistein, daidzein and their combination throughout differentiation (0, 1, 5, 10, 20, 50 µmol/L)
for 8 days. Total RNA was extracted at day 8 and subjected to RT-PCR. PPARγ mRNA levels were quantified and
normalized with β-actin mRNA. The values are expressed as fold changes, compared with control (vehicle), which
was arbitrarily set to 1; one independent experiment.
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Wnt10b
10b expression was not affected by soy isoflavones treatments, however, rosiglitazione
seems too repress the expression of Wnt
Wnt10b (Fig.11).
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Figure 11. Wnt10b mRNA expression in 3T3-L1 cells treated with genistein (A), daidzein
(B) or their combinations (C).
3T-L1 cells were grown and differentiated with the differentiation cocktail in the absence and presence of varying
concentrations of genistein, daidzein and their combination throughout differentiation (0, 1, 5, 10, 20, 50 µmol/L)
for 8 days. Total RNA was extracted at day 8 and subjected to RT-PCR. PPARγ mRNA levels were quantified and
normalized with β-actin mRNA. The values are expressed as fold changes, compared with control (vehicle), which
was arbitrarily set to 1; one independent experiment.
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2.5 Discussion
Epidemiological data and clinical studies in humans have shown that higher intake of dietary soy
isoflavones correlate with lower incidence of diabetes and improved insulin sensitivity [77,78].
In vitro cell culture studies however have showed controversy effects of soy isoflavones on the
activation of PPARγ, a nuclear transcription factor and expression of its downstream target genes
[59, 60, 78] mainly due to supra-physiological concentrations.
It is unclear whether potential benefits are mediated by the additive effects of multiple
isoflavones components or the concentration of a single isoflavone because most clinical studies
have used soy protein containing several different isoflavones.
Here we showed that soy isoflavones stimulated adipocyte differentiation using the 3T3-L1 cell
line, a well-established in vitro model of adipocyte differentiation that is more sensitive and thus
more responsive to physiological doses. We further showed that when combined, daidzein and
genistein increased more lipid accumulation at lower dose than individual compounds (Fig.6).
Dong X et al [83] have shown that when combined, genistein and daidzein at low dose has a
preventive synergistic effects on human prostate cancer compared to individual compound.
However, to our knowledge, this is the first data to show the additive effect of soy main
isoflavones on adipocyte differentiation.
The effects of soy isoflavones whether alone or combined on adipocyte differentiation were
comparable with regard to PPARγ mRNA expression particularly at 20 µmol/L, but does not
completely correlate with C/EBPα mRNA expression. From our data, due to the limited sample
size, we can only suggest that there is a trend that the increase in adipocyte differentiation by soy
isoflavones, correlate with the expression of the key adipocyte transcription factor, PPARγ
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especially at 20µmol/L (Fig.7). Kae Won Choa et al [58], similarly showed that daidzein and its
metabolite equol enhance PPARγ expression at low doses. The anti-adipogenic effect of
genistein at 50 µmol/L that we observed has also been reported. Genistein at both 50 and 100
µmol/L has been shown to inhibit adipogenesis of 3T3-L1 cells [83], presumably through its
inhibitory effects on tyrosine phosphorylation of multiple signaling molecules.
Because

PPARγ is the molecular target for TZD antidiabetic drugs that improve insulin

sensitivity and since insulin-stimulated glucose transport is regulated by expression of key
insulin signaling molecules such as GLUT4 [81], we have examined whether soy isoflavones
would affect the expression of GLUT4 expression at mRNA level. There is a trend that genistein
and daidzein alone or combined increased expression of GLUT4 mRNA; the stimulatory effect
of the combination was greater than that of individual compounds (Fig. 9), indicating that the
enhanced insulin sensitivity and glucose uptake observed in intervention studies by soy
isoflavones may be mediated in part by up-regulation of GLUT4 expression.
Since Wnt10b has been shown to be anti-adipogenic, and Wnt5b has been shown, when present,
to repress the anti-adipogenic effect of Wnt10b, we determined whether the effect of soy
isoflavones on adipocyte differentiation would be mediated by the Wnt signaling pathway. Our
data showed that there is a trend that genistein and daidzein alone or combined do not affect
Wnt10b mRNA expression while at 20 µm/L Wnt5b expression seems to be up-regulated.
However the antidiabetic drug, rosiglitazione seems to exert its anti-diabetic effect through the
inhibition of Wnt10b expression (Fig.11). This observation is consistent with studies that have
shown that TZD drugs inhibit Wnt signaling pathway [84].
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CHAPTER3
CONCLUSION & FUTURE DIRECTIONS
3.1 Summary
There is a strong link between obesity and T2DM. In insulin resistant states, such as obesity and
type 2 diabetes, fat depots contain a high proportion of large-lipid filled adipocytes that are
poorly functioning. It is therefore necessary to ensure the differentiation of newly formed
adipocytes that are highly insulin sensitive in order to prevent T2DM. There have been
increasing efforts to identify natural compounds to be used as anti-diabetic products with fewer
side effects [77]. Epidemiological data strongly suggest that consumption of soy is associated
with reduced incidence of diabetes and T2DM-related symptoms [79,80], which has led the Food
and Drug Administration to approve cardiovascular health claims for soy protein intake.

In

summary, our results suggest that soy isoflavones genistein and daidzein alone or combined
increased adipocyte differentiation particularly at a concentration of 20µm/L. The stimulation of
adipocyte differentiation is even greater when the two individual compounds are combined
.

indicating a potential additive effect.

Adipocyte differentiation is enhanced through PPARγ activation and the downstream responses
to PPARγ activation include increase in the expression of GLUT4 mRNA, which might explain
the enhanced glucose uptake and insulin sensitivity associated with soy consumption. However,
from our data, soy isoflavones effect on Wnt signaling pathway is unclear. Genistein and
daidzein alone or in combination did not show an effect on the anti-adipogenic Wnt signal,
Wnt10b while there is a trend that Wnt5b expression is up-regulated by soy isoflavones at
mRNA levels. Further studies are needed to elucidate the mechanisms of combined soy
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isoflavones effect on adipocyte differentiation and Wnt signaling pathway both at mRNA and
protein levels at early and late stage of the differentiation process.

3.2 Limitations
There are some limitations of the work presented here that are important to discuss. First is that
we use only one cell line to elucidate the mechanism through which soy isoflavones might exert
their effect on adipocyte differentiation. It is important to use other cell types to see if the
concentrations used and the responses observed vary according to cell types. However, 3T3-L1
cell lines constitute a good model to study the mechanisms in vitro.
A second limitation is that we only looked at the mRNA expression and we did not analyze
protein expression. The responses at mRNA levels may be different from that at protein levels.
A third limitation is the semi-quantitative nature of the regular PCR we used, which is a less
precise quantification compared to Real-Time PCR. Nonetheless, regular PCR has been used by
many researchers and allowed to understand many in vitro mechanistic aspects of isoflavones
action.
Another limitation is sample size. Most of the work presented here is in the preliminary stage
and needs to be repeated in order to gain statistical significance. However we were able to gain
valuable insight from these initial findings and open the door to a number of research questions
that could be addressed in the future.
Finally a major limitation not encountered here but commonly encountered with human
supplementation trials of soy isoflavones is bioavailability. Even though pharmacological doses
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of soy isoflavones might be able to be used, absorption is still variable from individual to
individual because of the gut microflora’s ability to metabolize the isoflavones. One possible
way to overcome this limitation is through the use of nanoparticle isoflavones delivery.

3.3 Significance of Findings
In vivo animal studies have shown soy isoflavones to ameliorate metabolic syndrome,
specifically insulin resistance, hyperglycemia, and weight gain. Our findings here of soy
isoflavones effect on adipocytes help understand the mechanisms behind their in vivo effects.
The significance of this work is that it focuses on a possible simple nutritional intervention that
could safely ameliorate the adverse insulin resistance associated with obesity by enhancing
adipocyte differentiation and insulin sensitivity. The new knowledge generated from these
preliminary data will be beneficial by giving an important piece of the scientific foundation that
could bring new avenues of investigation, prevention and possible treatment of obesityassociated insulin resistance, and thereby help lessen the adverse health burden of obesity.

3.4 Future Research Directions
Although our findings here suggest soy isoflavones increase adipocyte differentiation specially
when combined through PPARγ and Wnt5b up-regulation, this effect should be further
confirmed in vitro through the use of (1) a more accurate mRNA quantification method, Real
Time-PCR, (2) Western blotting, to determine the response at protein levels, (3) both at early and
late stage of the differentiation process and (4) through the use of human cell lines that may
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behave differently than 3T3-L1 pre-adipocyte because of pluripotency stage. Once soy
isoflavones effect has been confirmed in vitro, animal studies should be employed in order to
determine soy isoflavones ability to increase adipogenesis and glucose uptake in various adipose
depots (subcutaneous and visceral adipocytes). This will allow to determine optimal soy
isoflavones intake needed to maximize health benefits.
To further confirm our preliminary findings, our experiments should be repeated to gain validity.
Next it would be of interest to determine the relationship between the effect of soy isoflavones
on adipocyte differentiation and Wnt signaling. The downstream genes of Wnt signaling c-myc
and cycline D1 expression should be determined both at mRNA and protein levels. Also βcatenin phosphorylation could be determined by studying the kinase activity. Finally, soy
isoflavones could be used in the presence and absence of a Wnt inhibitory agent to further
elucidate the mechanism(s) of Wnt dependency.
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